Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047501 | 0.87 | — | — | |
| SCHEMBL8979753 | 0.86 | HAO1 (0.44) | ALDH1A1CES2CES1TSHRHAO1 | |
| SCHEMBL16425793 | 0.84 | TSHR (0.40) | ALDH1A1TSHRF2RL1HSD17B10HPGD | |
| Alcohol SCHEMBL28241943 | 0.83 | ALDH1A1 (0.40) | ALDH1A1CES2CES1HDAC3HDAC1 | |
| SCHEMBL27441199 | 0.83 | ALDH1A1 (0.40) | ALDH1A1CES2CES1HDAC3HDAC1 | |
| SCHEMBL1701664 | 0.82 | CES2 (0.53) | ALDH1A1CES2CES1HDAC3HDAC1 | |
| SCHEMBL27441211 | 0.79 | ALDH1A1 (0.46) | ALDH1A1TSHRF2RL1NPSR1KDM4E | |
| SCHEMBL3545243 | 0.79 | TSHR (0.59) | ALDH1A1TSHRHSD17B10HPGDKDM4E | |
| SCHEMBL11434918 | 0.79 | CES2 (0.50) | ALDH1A1CES2CES1HDAC3HDAC1 | |
| SCHEMBL3126473 | 0.79 | CES2 (0.50) | ALDH1A1CES2CES1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131055-A1 | FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-0580336-B1 | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO PERFUMERY CO LTD (JP) | 1998-09-30 | — | — | EP | disclosed |
| US-5565464-A | Compounds having angiotensine II antagonistic activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1996-10-15 | — | — | US | disclosed |
| US-5412109-A | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1995-05-02 | — | — | US | disclosed |
| US-5315013-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-24 | — | — | US | disclosed |
| US-5306834-A | Catalytic hydrogenation of 4-methylene-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0580336-A1 | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-01-26 | — | — | EP | disclosed |
| EP-0323841-B1 | SUBSTITUTED PYRROLE, PYRAZOLE AND TRIAZOLE ANGIOTENSIN II ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-08-04 | — | — | EP | disclosed |
| EP-0536105-A1 | Ruthenium(II)-binap diketonate complexes | MONSANTO COMPANY (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5189048-A | Hypotensive agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-02-23 | — | — | US | disclosed |
| WO-1993003018-A1 | COMPOUNDS HAVING ANGIOTENSINE II ANTAGONISTIC ACTIVITY | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1993-02-18 | — | — | WO | disclosed |
| US-5144050-A | Hydrogenation Catalysts | MONSANTO COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| US-5093346-A | Hypotensive agents, congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-03 | — | — | US | disclosed |
| US-5081127-A | Hypotensive agents and treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-5043349-A | Hypotensive agents, treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| US-5015651-A | Triazole derivatives for treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0323841-A2 | Substituted pyrrole, pyrazole and triazole angiotensin II antagonists | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131055-A1 | FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | MET, RET, ERBB4 | ALDH1A1 709/4885CES2 3366/4885CES1 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.